ArticleFrontiers in oncology2026

Overall survival after relapse in high-risk neuroblastoma: an adjusted indirect comparison of post-relapse dinutuximab beta, historical controls, and relapse after first-line dinutuximab beta maintenance.

Holger N Lode et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.